Immunotherapeutic approaches in chronic myelogenous leukemia

References

• Molldrem J J, Lee P P, Wang C, Felio K, Kantarjian H M, Champlin R E, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018–1023
   PubMed Web of Science ®Google Scholar
• Gannage M, Abel M, Michallet A S, Delluc S, Lambert M, Giraudier S, et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol 2005; 174: 8210–8218
   PubMed Web of Science ®Google Scholar
• Bocchia M, Wentworth P A, Southwood S, Sidney J, McGraw K, Scheinberg D A, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA Class I molecules. Blood 1995; 85: 2680–2684
   PubMed Web of Science ®Google Scholar
• Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang S Y, Sette A, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87: 3587–3592
   PubMed Web of Science ®Google Scholar
• Yotnda P, Firat P, Garcia-Pons F, Garcia Z, Gourru G, Vernant J P, et al. Cytotoxic T-cell response against the chimeric p210 BCRABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998; 101: 2290–2296
   PubMed Web of Science ®Google Scholar
• Buzyn A, Ostankovitch M, Zerbib A, Kemula M, Connan F, Varet B, et al. Peptides derived from the whole sequence of BCRABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol 1997; 27: 2066–2072
   PubMed Web of Science ®Google Scholar
• Clark R E, Dodi I A, Hill S C, Lill J R, Aubert G, MacIntyre A R, et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98: 2887–2893
   PubMed Web of Science ®Google Scholar
• Posthuma E FM, Falkenburg J HF, Apperley J F. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukaemia. Blood 1999; 93: 3863–3865
   PubMed Web of Science ®Google Scholar
• Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune response. Blood 2000; 95: 1781–1787
   PubMed Web of Science ®Google Scholar
• Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos E B, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2003; 103: 1037–1042
   PubMed Web of Science ®Google Scholar
• Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365: 657–662
   PubMed Web of Science ®Google Scholar
• Li A, Qiao Y, Liu B, Laska E J, Chakravarthi P, Kulko J M, et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 2005; 11: 4460–4468
   PubMed Web of Science ®Google Scholar
• Gutterman J U. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91: 1198–1205
   PubMed Web of Science ®Google Scholar
• Harada H, Taniguchi T, Tanaka N. The role of interferon regulatory factors in the interferon system and cell growth control. Biochimie 1998; 80: 641–650
   PubMed Web of Science ®Google Scholar
• Schmidt M, Nagel S, Proba J, Thiede C, Ritter M, Waring J F, et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 1998; 91: 22–29
   PubMed Web of Science ®Google Scholar
• Schmidt M, Hochhaus A, Nitsche A, Hehlmann R, Neubauer A. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-α. Blood 2001; 97: 3648–3650
   PubMed Web of Science ®Google Scholar
• Hao S X, Ren R. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol 2000; 20: 1149–1161
   PubMed Web of Science ®Google Scholar
• Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, Rosenbauer F, et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996; 87: 307–317
   PubMed Web of Science ®Google Scholar
• Tsujimura H, Tamura T, Ozato K. Cutting edge: IFN consensus sequence binding protein/IFN regulatory factor 8 drives the development of type I IFN-producing plasmacytoid dendritic cells. J Immunol 2003; 170: 1131–1135
   PubMed Web of Science ®Google Scholar
• Silver R T, Woolf S H, Hehlmann R, Appelbaum F R, Anderson J, Bennett C, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999; 94: 1517–1536
   PubMed Web of Science ®Google Scholar
• Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, et al. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood 2001; 98: 3074–3081
   PubMed Web of Science ®Google Scholar
• Baccarani M, Rosti G, de Vivo A, Bonifazi F, Russo D, Martinelli G, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002; 99: 1527–1535
   PubMed Web of Science ®Google Scholar
• Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau J L, Maloisel F, et al. Interferon alfa-2B combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997; 337: 223–229
   PubMed Web of Science ®Google Scholar
• O'Brien S G, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2003; 348: 994–1004
   PubMed Web of Science ®Google Scholar
• Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker B J, Larson R A, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006; 108: 1478–1484
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin A S, La Rosee P, Muller M C, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196
   PubMed Web of Science ®Google Scholar
• Lucy J E, Jorgensen H G, Mountford J C, Holyoake T L. Punish the parent not the progeny. Blood 2005; 105: 1862–1866
   PubMed Web of Science ®Google Scholar
• Sorel N, Bonet M L, Guillier M, Guilhot F, Brizard A, Turhan A G. Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem Biophys Res 2004; 323: 728–730
   PubMed Web of Science ®Google Scholar
• Lipton J H, Khoroshko N D, Golenkov A K, Abdulkadyrov K M, Nair K M, Raghunadharao D, et al. The Pegasys CML Study Group. Two-year survival data from a randomized study of peginterferon alfa-2a(40KD) vs interferon alfa-2a in patients with chronic phase chronic myelogenous leukemia. Blood 2003; 102(Suppl 1)3363a
   Google Scholar
• Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, et al. Imatinib an pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia. Blood 2004; 104: 4245–4251
   PubMed Web of Science ®Google Scholar
• Berger U, Hochhaus A, Pfirrmann M, Schoch C, Reiter A, Ehninger G, et al. Concept, feasibility and results of the randomized comparison of imatinib combination therapies for chronic myeloid leukemia: the german CML-study IV. Blood 2005; 106(Suppl 1)1083a
   Google Scholar
• Guerci A, Nicolini F, Maloisel F, Corm S, Legros L, Rigal-Huguet F, et al. Randomized comparison of imatinib with imatinib combination therapies in newly diagnosed chronic myelogenous leukaemia patients in chronic phase: design and first interim analysis of a phase III trial from the French CML group. Blood 2005; 106(Suppl 1)168a
   Google Scholar